$MDCX

Medicus Pharma Ltd.

Medicus Pharma is a clinical-stage, multi-strategy biotechnology company that advances therapeutic assets through Phase 2 proof-of-concept studies, with the aim of pursuing out-licensing or strategic partnerships with established pharmaceutical companies for later-stage development and commercialization. It identifies, evaluates, acquires and in-licenses assets and businesses, and operates through SkinJect and Antev. SkinJect develops a doxorubicin-containing dissolvable microneedle array, D-MNA, for non-melanoma skin cancers, especially basal cell carcinoma, and Gorlin Syndrome. Antev develops Teverelix, a gonadotrophin-releasing hormone antagonist for advanced prostate cancer and acute urinary retention prevention. Medicus Pharma is headquartered in West Conshohocken, Pennsylvania.

1
3
1

No SEC Form 4 filings for $MDCX in the last 30 days.

See all $MDCX insider activity →
Med

Small cap wrap: Phunware, Trust Stamp, Medicus Pharma, TNR

TNR Gold (TSX-V:TNR, OTC:TRRXF) agreed to a $122M acquisition by Altius Minerals at a 60% premium. Grey Matters Health (CSE:GREY, OTCQB:AGNPD) gained Medicare/Medicaid accreditation. Snail Inc (NASDAQ:SNAL) received a positive analyst note after Q3 revenue growth. Summit Therapeutics (NASDAQ:SMMT) shares fell 12.69% after FDA rejection. Citi initiated coverage of Amaroq Minerals (AIM:AMRQ, TSX-V:AMRQ) with a 'buy' rating. BioVie (NASDAQ:BIVI, NASDAQ:BIVIW) presented Long COVID trial findings.

Medicus Pharma raises $4.25M in CEO-led financings

Medicus Pharma (MDCX) raised $4.25M in equity financings, including $1.25M from a private placement led by CEO Dr. Raza Bokhari at $1.72 per share. The remaining $3M came via a registered direct offering. Funds will support working capital, CD228V development, and potential debt repayment. The company also exchanged $10.5M debt for preferred shares and conducted $350K in at-the-market share sales.

Medicus Pharma Ltd. (MDCX): Entry into a Material Definitive Agreement

Medicus Pharma Ltd. (MDCX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. Exchange Agreement On November 13, 2026, Medicus Pharma Ltd. (the "Company") entered into and closed an exchange agreement (the "Exchange Agreement") with Streeterville Capital, LLC (the "Investor"). Pursuant to the Exchange

MDCX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 5 news stories mentioning MDCX (Medicus Pharma Ltd.). Coverage has been balanced: 1 bullish, 3 neutral, and 1 bearish.

Recent MDCX coverage spans corporate actions, earnings and mergers & acquisitions.

What's driving MDCX

AlphAI scores every news story that mentions MDCX with an AI model for sentiment and relevance, and aggregates insider trades from Medicus Pharma Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $MDCX

Score

Small cap wrap: Phunware, Trust Stamp, Medicus Pharma, TNR

TNR Gold (TSX-V:TNR, OTC:TRRXF) agreed to a $122M acquisition by Altius Minerals at a 60% premium. Grey Matters Health (CSE:GREY, OTCQB:AGNPD) gained Medicare/Medicaid accreditation. Snail Inc (NASDAQ:SNAL) received a positive analyst note after Q3 revenue growth. Summit Therapeutics (NASDAQ:SMMT) shares fell 12.69% after FDA rejection. Citi initiated coverage of Amaroq Minerals (AIM:AMRQ, TSX-V:AMRQ) with a 'buy' rating. BioVie (NASDAQ:BIVI, NASDAQ:BIVIW) presented Long COVID trial findings.

Medicus Pharma raises $4.25M in CEO-led financings

Medicus Pharma (MDCX) raised $4.25M in equity financings, including $1.25M from a private placement led by CEO Dr. Raza Bokhari at $1.72 per share. The remaining $3M came via a registered direct offering. Funds will support working capital, CD228V development, and potential debt repayment. The company also exchanged $10.5M debt for preferred shares and conducted $350K in at-the-market share sales.

$MDCXMedOffering· $3M · closed

Medicus Pharma Ltd. (MDCX): Entry into a Material Definitive Agreement

Medicus Pharma Ltd. (MDCX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. Exchange Agreement On November 13, 2026, Medicus Pharma Ltd. (the "Company") entered into and closed an exchange agreement (the "Exchange Agreement") with Streeterville Capital, LLC (the "Investor"). Pursuant to the Exchange

Medicus Pharma reports Q3 results, outlines portfolio strategy

Medicus Pharma (MDCX) reported a Q3 2026 net loss of $15.2M, narrower than the $16.0M loss in Q3 2025. Operating expenses decreased to $14.5M. For the nine months, net loss was $35.9M, up from $27.3M. The company has $13.1M in cash and raised $42.6M in financings. Medicus plans to focus on CD228V for melanoma and a potential $135M merger for SkinJect, with projected $3M costs. Management expects reduced operating expenses.

Medicus Pharma Ltd: Medicus Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Medicus Pharma (NASDAQ:MDCX) reported Q3 2026 results, highlighting CD228V as its main focus. The company partnered with Pfizer for CD228V, a melanoma-targeting ADC. Medicus also announced a potential SPAC deal for SkinJect at a $135M valuation. Q3 financials show $13.1M in cash, $15.2M net loss, and reduced operating expenses. The company aims to advance its portfolio through strategic partnerships and capital-efficient resource allocation.

$MDCXHighAI 9/10M&A· $135M · announced

Medicus Pharma Announces Proposed SkinJect® Business Combination and Concurrent Financing

Medicus Pharma Ltd. (MDCX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Medicus Pharma Announces Proposed SkinJect® Business Combination and Concurrent Financing The proposed transaction would value SkinJect® at ~$135 million and include financing at closing to support the SKNJCT-005 NDA-enabling study in Gorlin Syndrome patients Philade

Medicus Pharma Regains Nasdaq Minimum Share Price Compliance

Medicus Pharma (MDCX) regained compliance with Nasdaq's minimum share price requirement, maintaining a closing bid price of at least $1 for 10 consecutive days. This resolves a listing deficiency, but the company cautioned future compliance is not guaranteed. Medicus filed a Form 8-K with the SEC detailing the compliance determination.

Related tickers